

Financial Interest Forms for All Clinical Investigators on a VCU Faculty Held IND or IDE

- 1. All VCU employees who are Clinical Investigators must complete the AIRS system using the reporting guidelines in the PHS Compliant VCU COI Management Policy.
- 2. All Clinical Investigators at all sites must complete the VCU Certification of Financial Interests. If any items are marked yes also complete a VCU Disclosure of Financial Interests form. Review the FDA disclosable Financial Interests below prior to completing the forms.
- 3. External to VCU Clinical Investigators receiving PHS, PHS adherent funding for the conduct of this study must complete the Subaward Recipient Commitment Form. If deferring COI management to VCU you must also complete the AIRS system. The VCU study team can assist you with this. If not deferring, you must comply with your institutions COI management system.
- 4. Return the forms to the VCU IND/IDE Sponsor

a.	Secure Fax
b.	Secure Email
c.	Mail

FDA Disclosable Financial Interests and Arrangements from Guidance for Clinical Investigators, Industry, and FDA Staff: Financial Disclosure by Clinical Investigators

The financial interests, arrangements, and payments that must be disclosed (see 21 CFR § 54.4(a)(3), referred to herein as "disclosable financial interests and arrangements") are described below. Note that the dollar amounts that trigger reporting are the combined financial interests of the investigator, spouse, and dependent children.

- 1. Any compensation made to the investigator by any sponsor of the covered clinical study in which the value of compensation could be affected by study outcome.
- 2. A proprietary interest in the tested product including, but not limited to, a patent, trademark, copyright or licensing agreement.
- 3. Any equity interest in any sponsor of the covered clinical study, i.e., any ownership interest, stock options, or other financial interest whose value cannot be readily determined through reference to public prices. The requirement applies to interests held during the time the clinical investigator is carrying out the study and for one year following completion of the study.
- 4. Any equity interest in any sponsor of the covered study if the sponsor is a publicly held company and the interest exceeds \$50,000 in value. The requirement applies to interests held during the time the clinical investigator is carrying out the study and for one year following completion of the study.

5. Significant payments of other sorts (SPOOS) are payments that have a cumulative monetary value of \$25,000 or more and are made by any sponsor of a covered study to the investigator or the investigator's institution during the time the clinical investigator is carrying out the study and for one year following completion of the study. This would include payments that support activities of the investigator (e.g., a grant to the investigator or to the institution to fund the investigator's ongoing research or compensation in the form of equipment), exclusive of the costs of conducting the clinical study or other clinical studies, or to provide other reimbursements such as retainers for ongoing consultation or honoraria. See Section IV, Questions <u>C.4</u>, <u>C.5</u>, and <u>C.6</u> for additional information on SPOOS.

Reference: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM341008.pdf

VCU Policy: Conflicts of Interest in Research

http://policy.vcu.edu/sites/default/files/Conflict%20of%20Interests%20in%20Research.pdf

Revision History: Version1: June 13, 2014 Version2: August 26, 2015

VCU Certification of Financial Interest of Clinical Investigators

Title of Clinical Study			
Identity of Investigat	ional Drug/Device:		
The Sponsors (as define part-time employee of		study are listed in the table. For ea	ach indicate if you are a full or
Sponsor			Employee Yes/No
VCU/VCUHS			
based (i.e., investigator		n the above-named clinical study be red IND or IDE application, I certify or each statement):	=
[] I do [] I do not	•	• •	al interest (i.e., equity interest) in the all drug or device being evaluated in the
[] I do [] do not	investigational drug or do to, a patent or patent int arrangement tied to a cu	financial interest (i.e., proprietary in levice being evaluated in the clinical terest, trademark, copyright, licensi urrent or future right to receive roya al commercialization of the drug or	study; including, but not limited ng agreement, or any alties associated with the
[] I will [] I will not	the respective investigati study; nor do I anticipate following completion of t include, but are not limit	the company (other ones for which tional drug or device during the term e receiving payments from the complete clinical study. Applicable payments to, grants to fund projects or resents, equipment, or retainers for co	n of the conduct of the clinical pany during a 1 year period nents (i.e., financial interest) search or compensation in the
Clinical Investigators is	required. For VCU/VCUHS e ceiving PHS, PHS adherent fu	ffirmative, completion of the Disclosemployees you must also complete unding for this study and deferring	the AIRS system. For External
Name of Clinical In	vestigator (Printed or Typed	3)	
Signature of Clinica	al Investigator	Date	

VCU Disclosure of Financial Interest of Clinical Investigators

of Clinical Study:	
•	
I have participated in financial arrangements or helf, my spouse, and children): (Check all applicab	Financial Disclosure by Clinical Investigators, I hereby disclose hold financial interests as follows (this collectively includes le boxes.) Do not include financial arrangements or financial the Sponsor. FDA disclosable financial interests.
I am an employee) that owns the investigation	en the company (other than those marked as sponsors for which al drug or device being evaluated in the above named clinical to me for conducting or participating in the clinical study could
employee) that owns the investigational drug of	s) of other sorts from the company (other than those marked as or device being evaluated in the abovenamed clinical study; such tion in the form of equipment, retainer for ongoing consultation
Any proprietary interest in the investigational of	lrug or device being evaluated in the above-named clinical study
	e company (i.e., other than VCU/VCUHS) that owns the in the above-named clinical study.
teps (i.e., management plan) taken by your depa tigator of the clinical study to minimize the pote	ements and interests. Also attach to this form, a description of rtment chair and/or dean, the University, or the principal ntial bias of clinical study results related to your disclosed
IS adherent funding for this study and deferring t	ne AIRS system. For External Clinical Investigators receiving PHS o VCU for COI management you must also complete the AIRS
Name of Clinical Investigator (Printed or Typ	ed)
Signature of Clinical Investigator	Date
	cipal Investigator: tity of Investigational Drug/Device: asor(s) of this study compliance with the provisions of 21 CFR Part 54, It have participated in financial arrangements or helf, my spouse, and children): (Check all applicable ests if you are employed full time or part time by Any financial arrangement entered into between I am an employee) that owns the investigation as study, whereby the value of the compensation be influenced by the outcome of the study; Any significant payments (i.e. financial interests employee) that owns the investigational drug of as a grant to fund ongoing research, compensation or honoraria; Any proprietary interest in the investigational of the investigational drug or device being evaluated in the tothis form the details of your financial arrangements (i.e., management plan) taken by your depatigator of the clinical study to minimize the potential arrangements or interests. CU/VCUHS employees you must also complete the compensation of the clinical study to minimize the potential arrangements or interests.